Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | withdrawn | Phase 1 / Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT02028039 | IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 6, 2014 | clinicaltrials |
| NCT01478074 | ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Altor BioScienceINDUSTRY | 1 | Jan 3, 2014 | clinicaltrials |
| NCT01247688 | Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies(UCALL) | withdrawn | N/A | 0 | Baylor College of MedicineOTHER | 0 | Dec 12, 2013 | clinicaltrials |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Dec 10, 2013 | clinicaltrials |
| NCT00129558 | A Study to Evaluate PT-523 in Patients With Refractory Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00957320 | Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | withdrawn | Phase 3 | 0 | Eisai Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Nov 6, 2013 | clinicaltrials |
| NCT00943709 | Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia | withdrawn | Phase 3 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00457574 | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Gemin XINDUSTRY | 0 | Aug 28, 2013 | clinicaltrials |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 1 / Phase 2 | 0 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01671813 | Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT01044004 | Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jul 23, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | The Cleveland ClinicOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(GCS-100LE) | withdrawn | Phase 1 / Phase 2 | 0 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT01492569 | Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Jun 12, 2013 | clinicaltrials |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00968461 | Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 15, 2013 | clinicaltrials |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT01508260 | Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid Overload | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT00499668 | Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer | withdrawn | N/A | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 2, 2013 | clinicaltrials |
| NCT00601991 | A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 2, 2013 | clinicaltrials |
| NCT00030355 | Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 22, 2013 | clinicaltrials |
| NCT00003435 | Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Feb 20, 2013 | clinicaltrials |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 15, 2013 | clinicaltrials |
| NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 3 | 0 | Centocor, Inc.INDUSTRY | 14 | Jan 28, 2013 | clinicaltrials |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00081068 | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 5 | Jan 8, 2013 | clinicaltrials |
| NCT00541424 | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2012 | clinicaltrials |
| NCT01568632 | Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Nov 21, 2012 | clinicaltrials |
| NCT00002761 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Columbia UniversityOTHER | 0 | Nov 19, 2012 | clinicaltrials |
| NCT01649622 | Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 8, 2012 | clinicaltrials |
| NCT00972101 | Infusion of Expanded Cord Blood T Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 11, 2012 | clinicaltrials |
| NCT00006090 | Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 10, 2012 | clinicaltrials |
| NCT00301912 | Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Oct 2, 2012 | clinicaltrials |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Sep 7, 2012 | clinicaltrials |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 3, 2012 | clinicaltrials |
| NCT01168882 | Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies | withdrawn | Phase 1 | 0 | AgennixINDUSTRY | 0 | Aug 2, 2012 | clinicaltrials |
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00939172 | TTP607 in Refractory Solid Malignancies | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2014source: clinicaltrials